![Nilesh Kumar](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nilesh Kumar
Direktor/Vorstandsmitglied bei
Anokion SA
Profil
Dr. Nilesh Kumar ist ein unabhängiges Mitglied des Verwaltungsrats von Checkmate Pharmaceuticals, Inc. ein unabhängiges Mitglied des Verwaltungsrats von Morphic Holding, Inc. ein unabhängiges Mitglied des Verwaltungsrats von Cirius Therapeutics, Inc. ein Partner bei Novo Ventures (US), Inc. und ein Senior Investment Director bei Merck KGaA. Er ist Mitglied des Board of Directors bei Checkmate Pharmaceuticals, Inc, Morphic Holding, Inc, Morphic Therapeutic, Inc, Cirius Therapeutics, Inc, Anokion SA, Disc Medicine, Inc, Kanyos Bio, Inc, Rgenix, Inc. und Tarveda Therapeutics, Inc. Dr. Kumar war zuvor als unabhängiger Direktor bei Milestone Pharmaceuticals, Inc. angestellt, ein Principal bei Atlas Venture, Inc. und ein Principal bei Codon Devices, Inc. sowie ein Principal bei Infinity Pharmaceuticals, Inc. Darüber hinaus war er Vorstandsmitglied bei Auxogyn, Inc, Canbex Therapeutics Ltd, Padlock Therapeutics, Inc, Progyny, Inc, Raze Therapeutics, Inc, TocopheRx, Inc. und Translate Bio, Inc. Er erhielt seinen Bachelor-Abschluss von der University of Cambridge, einen MBA von der Harvard Business School und einen Doktortitel von der Harvard University.
Aktive Positionen von Nilesh Kumar
| Unternehmen | Position | Beginn |
|---|---|---|
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cancer | Direktor/Vorstandsmitglied | - |
Anokion SA
 Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Direktor/Vorstandsmitglied | - |
Cirius Therapeutics, Inc.
 Cirius Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company that develops therapies | Direktor/Vorstandsmitglied | 01.05.2017 |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Direktor/Vorstandsmitglied | 24.09.2018 |
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures US invests venture capital in biotechnology and life science companies throughout the US and Europe. Their typical investments are as equity ranging from 1 to 15 million Euro. The firm may invest at any stage of development of a business idea - from seed capital over private placements to IPOs and public companies and they may invest in any part of the world. | Private Equity Investor | 01.04.2015 |
Wellington Management Co. LLP (Private Equity)
 Wellington Management Co. LLP (Private Equity) Investment ManagersFinance Wellington Management invests in companies located in the United States. The firm targets companies operating in the fields of consumer, technology, healthcare, financial services, climate technology and biotechnology sectors. It provides financing for early stage to later stage capital requirements. | Private Equity Investor | 01.11.2021 |
Novo Holdings A/S (Denmark)
 Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Private Equity Investor | - |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements. | Private Equity Investor | 04.01.2015 |
Ehemalige bekannte Positionen von Nilesh Kumar
| Unternehmen | Position | Ende |
|---|---|---|
| MORC HOLD | Direktor/Vorstandsmitglied | 24.02.2022 |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Nilesh Kumar
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
78
Beziehungen ersten Grades
28
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 28 |
|---|---|
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Codon Devices, Inc.
 Codon Devices, Inc. Pharmaceuticals: MajorHealth Technology Produces pharmaceuticals & biorefineries for the production of industrial chemicals and bio-energy | Health Technology |
Milestone Pharmaceuticals, Inc.
 Milestone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cardiovascular medicines | Health Technology |
Translate Bio, Inc.
 Translate Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage mRNA therapeutics company that develops transformative medicines to treat diseases caused by protein | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novo Holdings A/S (Denmark)
Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Finance |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for early stage capital requirements. | Finance |
Infinity Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements. | Finance |
Canbex Therapeutics Ltd.
 Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain | Health Technology |
Auxogyn, Inc.
 Auxogyn, Inc. BiotechnologyHealth Technology Provides novel scientific and development biotechnology services | Health Technology |
Tarveda Therapeutics, Inc.
 Tarveda Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops cancer therapeutics and drugs | Health Technology |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures US invests venture capital in biotechnology and life science companies throughout the US and Europe. Their typical investments are as equity ranging from 1 to 15 million Euro. The firm may invest at any stage of development of a business idea - from seed capital over private placements to IPOs and public companies and they may invest in any part of the world. | Finance |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TocopheRx, Inc.
 TocopheRx, Inc. Medical SpecialtiesHealth Technology Develops novel therapies for treatment of infertility | Health Technology |
Anokion SA
Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Health Technology |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Develops medicines targeting protein-arginine deiminases | Health Technology |
Raze Therapeutics, Inc.
 Raze Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops oncology therapeutics | Health Technology |
Progyny, Inc.
 Progyny, Inc. Miscellaneous Commercial ServicesCommercial Services Provides fertility and family building benefits solutions | Commercial Services |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Health Technology |
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develop anti-cancer therapeutics | Health Technology |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cancer | Health Technology |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
Cirius Therapeutics, Inc.
Cirius Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company that develops therapies | Health Technology |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
Wellington Management Co. LLP (Private Equity)
Wellington Management Co. LLP (Private Equity) Investment ManagersFinance Wellington Management invests in companies located in the United States. The firm targets companies operating in the fields of consumer, technology, healthcare, financial services, climate technology and biotechnology sectors. It provides financing for early stage to later stage capital requirements. | Finance |
F-star Therapeutics Ltd.
 F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops antibodies therapeutics for cancer therapy | Health Technology |
